Interleukin-1beta Inhibition Attenuates Vasculitis in a Mouse Model of Kawasaki Disease.
Animals
Antibodies
/ administration & dosage
Aorta
/ pathology
Disease Models, Animal
Immunity, Innate
Interleukin-10
/ metabolism
Interleukin-1beta
/ immunology
Interleukin-6
/ metabolism
Male
Mice, Inbred DBA
Mucocutaneous Lymph Node Syndrome
/ drug therapy
Signal Transduction
/ drug effects
Time Factors
Tumor Necrosis Factor-alpha
/ metabolism
Kawasaki disease
Kawasaki disease model mouse
cytokine profile
interleukin-10
interleukin-1beta
Journal
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
ISSN: 1347-3409
Titre abrégé: J Nippon Med Sch
Pays: Japan
ID NLM: 100935589
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
28
5
2019
pubmed:
28
5
2019
medline:
27
11
2019
Statut:
ppublish
Résumé
Kawasaki disease (KD), a systemic vasculitis, is suspected to be related to abnormalities in innate immunity. Based on the important role of IL-1 signaling in innate immunity, we investigated the effects of an anti-IL-1β antibody using a Candida albicans water-soluble fraction (CAWS)-induced mouse model of KD. CAWS (0.5 mg/mouse) was injected intraperitoneally into 5-week-old DBA/2 mice on five consecutive days. An anti-Murine IL-1β antibody (01BSUR) was administered at various doses (2.5, 5.0, and 10.0 mg/kg) and time points (2 days before, same day, and 2, 5, 7, and 14 days after CAWS administration). After 4 weeks, vasculitis in the aortic root was investigated histologically. Cytokines including IL-1β, -6, -10, and TNF-α were also measured. Groups administered 01BSUR at all doses showed a significant reduction in the area of vasculitis. In addition, 01BSUR inhibited vasculitis until 7 days after CAWS administration. In the analysis of various time points, the level of IL-6 was lower in all groups compared to the CAWS only group, but the levels of IL-1β, TNFα, and IL-10 were lower when 01BSUR was administered before CAWS. On the other hand, TNFα and IL-10 levels were restored when 01BSUR was administered after CAWS, suggesting that 01BSUR may have additional effects beyond blocking IL-1β signaling. The anti-IL-1β antibody significantly attenuated CAWS-induced vasculitis. The mechanism of inhibiting vasculitis is thought to include inhibition of the IL-1β pathway and additional effects beyond blocking IL-1β signaling.
Sections du résumé
BACKGROUND
BACKGROUND
Kawasaki disease (KD), a systemic vasculitis, is suspected to be related to abnormalities in innate immunity. Based on the important role of IL-1 signaling in innate immunity, we investigated the effects of an anti-IL-1β antibody using a Candida albicans water-soluble fraction (CAWS)-induced mouse model of KD.
METHODS
METHODS
CAWS (0.5 mg/mouse) was injected intraperitoneally into 5-week-old DBA/2 mice on five consecutive days. An anti-Murine IL-1β antibody (01BSUR) was administered at various doses (2.5, 5.0, and 10.0 mg/kg) and time points (2 days before, same day, and 2, 5, 7, and 14 days after CAWS administration). After 4 weeks, vasculitis in the aortic root was investigated histologically. Cytokines including IL-1β, -6, -10, and TNF-α were also measured.
RESULTS
RESULTS
Groups administered 01BSUR at all doses showed a significant reduction in the area of vasculitis. In addition, 01BSUR inhibited vasculitis until 7 days after CAWS administration. In the analysis of various time points, the level of IL-6 was lower in all groups compared to the CAWS only group, but the levels of IL-1β, TNFα, and IL-10 were lower when 01BSUR was administered before CAWS. On the other hand, TNFα and IL-10 levels were restored when 01BSUR was administered after CAWS, suggesting that 01BSUR may have additional effects beyond blocking IL-1β signaling.
CONCLUSIONS
CONCLUSIONS
The anti-IL-1β antibody significantly attenuated CAWS-induced vasculitis. The mechanism of inhibiting vasculitis is thought to include inhibition of the IL-1β pathway and additional effects beyond blocking IL-1β signaling.
Identifiants
pubmed: 31130561
doi: 10.1272/jnms.JNMS.2019_86-206
doi:
Substances chimiques
Antibodies
0
Interleukin-1beta
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM